NCT07741773 · NOT YET RECRUITING
Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular Activity
This trial is testing whether a daily dietary supplement made from extra-virgin olive oil phenolics — the naturally occurring plant compounds in EVOO — can improve memory and brain-related biomarkers in people with mild cognitive impairment. Researchers will compare the supplement against a placebo over six months. Phase NA here means this is likely a feasibility or pilot study, not yet at the stage of a large effectiveness trial.
You may qualify if
- CDR (Clinical Dementia Rating) score of 0.5 OR MoCA (Montreal Cognitive Assessment) score of 18-25.
You're excluded if
- History or presence of vascular disease that may affect cognitive function
- History or presence of stroke within the past 1 year
- Recent transient ischemic attack (TIA) within the past 180 days
- History of severe, clinically significant CNS trauma
- History of intracranial tumor
- History or presence of kidney disease (eGFR \<60 mL/min/1.73m2)
- Presence of a pacemaker
- Presence of metal in the body
- Allergic to the MRI contrast agent "Multihance"
- Pregnancy
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-03